Novartis plans to shut down Sandoz North Carolina plant by 2023 end Ruchika Sharma12 Sept 2022 12:24 PM ISTZurich: Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on...
Novartis Kisqali adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer Ruchika Sharma11 Sept 2022 3:18 PM ISTBasel: Pharma major, Novartis, has announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program,...
Novartis Sandoz division to go independent Ruchika Sharma25 Aug 2022 2:33 PM ISTThe standalone Sandoz would be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in...
Novartis Lung cancer drug Canakinumab fails in Phase 3 trial Ruchika Sharma17 Aug 2022 4:15 PM ISTBasel: Novartis has recently announced that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of...
Zolgensma gene therapy caused two fatalities from liver failure, reports Novartis Ruchika Sharma14 Aug 2022 2:00 PM ISTBasel: Novartis AG on Thursday reported two patient fatalities due to acute liver failure following treatment with Zolgensma gene therapy used to...
Novartis donates Rs 16 Crore gene therapy to 23 month old Spinal Muscular Atrophy Type 1 patient Roshni Dhar9 Aug 2022 6:00 PM ISTA 23-month-old baby with Spinal Muscular Atrophy (SMA) Type 1, received a new lease of life with Swiss drugmaker Novartis coming forward to donate...
Health Bulletin 9/ August/ 2022 Roshni Dhar9 Aug 2022 5:27 PM ISTHere are the Top Health stories for the day:Telangana baby with rare genetic disease administered Rs 16 crore drugA 23-month-old baby with Spinal...
Novartis donates Rs 16 crore drug to 23 month old Spinal Muscular Atrophy Type 1 patient MD Bureau8 Aug 2022 4:16 PM ISTAccording to Praveen, they had registered their daughter under Managed Access Programme of Novartis and they received the information that the company...
CDSCO panel rejects Novartis Phase III CT protocol for Lanalumab Rahul Verma30 July 2022 6:33 PM ISTCiting that the clinical trial protocol missed some inclusion/exclusion criteria, the Subject Expert Committee (SEC) functional under Central Drug...
CDSCO panel nod to Novartis Ruxolitinib for acute and chronic graft versus host disease Rahul Verma24 July 2022 2:15 PM ISTIn response to the pharma major Novartis proposal for additional indication of Ruxolitinib Tablets 5/10/15/20 mg, the Subject Expert Committee (SEC)...
Novartis no longer expects earnings decline at under-review Sandoz unit Ruchika Sharma19 July 2022 12:41 PM ISTNew Delhi: Swiss drugmaker Novartis said earnings at its Sandoz unit, the maker of cheap generic drugs that might be put up for sale, would...
Novartis leaning toward spinoff of USD 25 billion generics arm: Bloomberg Ruchika Sharma3 July 2022 12:30 PM ISTNew Delhi: Novartis AG is leaning toward a spinoff of its generic-drug unit, as a challenging environment for leveraged buyouts makes a potential sale...
